Information on the origin of brain glutathione and the possibility of its transport from blood to brain is limited. We found a substantial uptake of 35S-labeled glutathione by the rat brain using the carotid artery injection technique. The brain uptake index of glutathione with and without an irreversible gamma-glutamyl transpeptidase inhibitor, acivicin, was similar. No significant differences in the regional uptake of labeled glutathione were found in rats pretreated with acivicin. The brain uptake index of tracer glutathione was similar to that of cysteine tracer and was lower than that of phenylalanine. The transport of oxidized glutathione (glutathione disfulfide) across the blood-brain barrier was not significantly different from that of sucrose, an impermeable marker. Brain radioactivity 15 s after carotid artery injection of labeled glutathione to rats pretreated with acivicin was predominantly in the form of glutathione. The in vivo glutathione uptake was saturable with an apparent Km of 5.84 mM. Amino acids, amino acid analogues, and other compounds [cysteine, phenylalanine, glutathione disulfide, gamma-glutamylglutamate, gamma-glutamyl pnitroanilide, 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid (BCH)] did not affect glutathione transport. Our data suggest that glutathione is transported across the bloodbrain barrier by a saturable and specific mechanism.
Introduction
Glutathione, reduced (GSH), gamma-glutamylcysteinylglycine, is an ubiquitous tripeptide in aerobic cells that plays a critical role in detoxification of peroxides and electrophilic toxins as a substrate for GSH peroxidase and GSH-S-transferase (1) (2) (3) (4) . It also may play a role in interorgan sulfur amino acid homeostasis as a storage form for cysteine (5) . This latter role is based on the fact that a circulating steady-state plasma GSH level which turns over rapidly is found in rodents and humans (5) . Nearly all of the GSH in plasma is derived from GSH synthesized in the cytosol of hepatocytes and released by carrier-mediated transport (6, 7) . Plasma GSH is cleared by the kidney and other organs such as intestine and lungs (8) (9) (10) . Two mechanisms of clearance have been described: direct uptake of GSH by carrier-mediated transport and breakdown of GSH by gamma-glutamyltranspeptidase (GGT)' and dipeptidases (1 1).
GSH is biosynthesized from precursor amino acids by two ATP-dependent enzymatic reactions (12) . Critical for the synthesis of GSH in most cells is the availability of cysteine (2) . Various cell types have distinct transport systems for the uptake of cystine and cysteine (13, 14) . The blood-brain barrier, along with hepatocytes, lymphocytes, and erythrocytes, lacks the cystine transport system (15) . The blood-brain barrier transport of cysteine is through the L system, whereas in the other cell types mentioned, cysteine transport is mediated by the ASC system (15, 16) .
GSH is abundant in the brain: both endothelium and astroglia contain millimolar concentrations of GSH (17, 18) . Since cysteine and GSH levels in plasma are ofthe same order of magnitude, we considered that, as an alternative to plasma cysteine, plasma GSH might play an important role in brain GSH homeostasis. Brain capillaries contain GGT activity on the luminal membrane which may serve to break down plasma GSH (19) . However, we considered that GSH may also be taken up intact as has been suggested in other organs that also have abundant GGT, such as intestine and lungs (8-1 1). Although there is some transport of peptides across the bloodbrain barrier, this transport is considered not to be of physiological significance (20, 21) . One previous report examined
[3H]GSH transport and showed negligible uptake (22) . How- ever, precautions to maintain GSH in the reduced form were not taken. Furthermore, we and others have found that commercially available [3H]glycine-GSH is highly impure (23 Ringer-Hepes buffer/l mM DTT at pH 7.4 was administered rapidly into the external carotid artery using a 27-gauge needle and the rat was decapitated (guillotine) 15 s later. The ipsilateral brain was removed within 30-40 s, rinsed in buffer, and blotted dry. In some experiments, hypothalamus and the frontal cortex, caudal cortex, and midbrain regions of the ipsilateral brain were dissected. The tissue samples were digested in Protosol at 50-550C for 2 h, and the digest after discoloration with H202 was counted in Aquasol in triplicate along with quench standards. Aliquots of the injectate mixture withdrawn from the syringe were used for dose assays. BUI% was calculated (27) GSH BUIs were also determined in acivicin-pretreated rats in the presence of varying concentrations of unlabeled GSH added to the tracer in the injectate. GSH solutions of varying concentrations were prepared (1-40 mM) in Hepes-Ringer buffer per 1 mM DTT. Solutions containing higher GSH concentrations (> 1 mM) became acidic and were adjusted to pH 7.4 to avoid effects of pH on the BUI (28) .
To study the inhibition ofGSH uptake by amino acids and analogs, phenylalanine (1 mM), cysteine (1, 20 mM), BCH (10 mM), gammaglutamylglutamate (10 mM), gamma-glutamyl p-nitroanilide (10 mM), and GSSG (20 mM) were added to the labeled injectate mixture in buffer per 1 mM DTT (except GSSG for which DTT was omitted).
The pH ofthe solutions was adjusted to 7.4 before the addition oflabel and carotid artery injection. GSH BUIs were determined in a separate group of acivicin-pretreated rats with tracer GSH alone and in the presence of the above amino acids.
To determine the molecular form of the radioactivity in brain The GGT activities in kidney and brain homogenates were 232±18.6 and 3.5±0.3 umol/min per g, respectively, before acivicin treatment, and decreased to below the measurable limit of the assay (< 0.1 smol/min per g) after administration of acivicin in vivo. The BUI of GSH with or without pretreatment with acivicin did not differ significantly (22.6±2.8%, n -24 vs. 26.62. 1%, n = 22, respectively). Fig. 1 -I -I that transport can occur at plasma levels that would exist in the brain capillary lumen. The finding of a lack of inhibition of brain GSH uptake by GSSG and other gamma-glutamyl compounds is of interest. GSH uptake in other organs such as kidney and intestine differs in that gamma-glutamyl compounds inhibit and presumably share the transport system for GSH (8) (9) (10) 32) . Thus, GSH transport in these organs may simply signify a transport system for the products of transpeptidation. However, the specificity for GSH in our studies is unique and suggests a different transport system. Since GSSG did not inhibit transport of GSH and itself had a low BUI, it is possible that the previous report of inability to identify [3H]GSH transport (22) was due to its conversion to GSSG, a non-transportable form.
Although most of our studies were performed in acivicinpretreated rats to avoid the effects of GGT, it should be noted that in the untreated rats a substantial fraction of the label was taken up in the intact form. Thus, even at tracer doses, GSH uptake can compete effectively with degradation mediated by GGT. This strongly suggests that even in the presence ofGGT activity, GSH transport as the intact form may occur. Furthermore, no detectable incorporation of cysteine into GSH occuffed under these experimental conditions for BUI determinations. Therefore, the labeled GSH in brain either in the presence or absence of acivicin pretreatment could not be accounted for by breakdown and de novo resynthesis of GSH. Clearly, more work will be required to precisely define the physiologic contributions of intact GSH transport vs. GGTinitiated breakdown and transport (and utilization) ofcysteine at the blood-brain barrier. The ultimate determination of the contribution of the competing pathways for handling GSH, namely GSH transport and GGT, at various plasma GSH concentrations also will require assessment of the availability to the brain of the products of the GGT reaction such as cysteinylglycine and gamma-glutamylcystine. It will also be important in future work to determine the contribution of cysteine transport and GSH synthesis vs. GSH transport in determining brain GSH. However, the present studies demonstrate for the first time that under physiologic conditions transport of GSH in its intact form can occur at the blood-brain barrier.
Two aspects of compartmentation of GSH in the brain deserve comment. Choroid plexus, which constitutes only a very small portion ofthe brain, is reported to have a higher rate ofsynthesis and turnover (33) compared with that ofthe whole brain (34, 35) . The release of GSH from choroid plexus accounts for the GSH found in the cerebrospinal fluid. Since the choroid plexus represents a very small portion ofthe brain, the BUI for GSH observed in our studies cannot be accounted for by uptake by the choroid plexus. Another concern about compartmentation not addressed in the present studies is whether the GSH removed from plasma is available only to endothelial cells or undergoes transcellular transport into the brain.
